Verastem, Inc. VSTM 深 滬
已收盤 02-06 16:00:00 美东时间
6.67
+0.390
+6.21%
華盛通- 最 高6.755
- 今 開6.36
- 成交量 127.87万股
- 最 低 6.36
- 昨 收 6.28
- 總市值 5.02亿
- 52周最高 11.245
- 市盈率 靜 --
- 換手率 1.70%
- 52周最低 4.01
- 委 比 15.49%
- 總股本 7531.98万
- 歷史最高 225.84
- 量 比 0.61
- 振 幅 6.29%
- 歷史最低 2.10
- 每 手 1
- 風險率 1.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 泰瑞达、Lumentum、哈贝尔、Enphase能源、西部数据获多家机构上调目标价；PayPal 、恩智浦、墨式烧烤遭多家机构下调目标价
今日重点评级关注：韦德布什：维持Replimune Group"跑赢大市"评级，目标价从18美元升至19美元；巴克莱：维持CytomX Therapeutics"超配"评级，目标价从8美元升至10美元
02-05 11:28
Verastem Oncology Expects $17.5M In Q4 2025 Revenues For AVMAPKI FAKZYNJA CO-PACK, Up From $12.5M In Q4 2024, While Advancing VS-7375 Development In 2026
Based on preliminary, unaudited results, Verastem expects AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of approximately $17.5 million for the fourth quarter of 2025 and approximately $30.9 million for
02-04 20:34
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[...
01-30 23:19
Verastem updates oncology strategy in new corporate presentation
An update from Verastem ( ($VSTM) ) is now available. On January 8, 2026, Veras...
01-09 05:51
优于标准疗法但仍不敌竞品 Immuneering(IMRX.US)胰腺癌疗法2期数据公布后盘后重挫21%
生物技术公司Immuneering Corp.(IMRX.US)在周三盘后交易中暴跌约21%，此前其公布了atebimetinib作为胰腺癌一线疗法的2a期临床试验结果。
01-08 09:01
Immuneering plummets following phase 2 data of atebimetinib for pancreatic cancer
Immuneering Corp. (IMRX) is down ~21% in after-hours trading Wednesday after posting phase 2a results on atebimetinib as a first-line treatment for pancreatic cancer. The biotech reported 64% overall ...
01-08 05:59
Verastem Ends Lung Cancer Trial, Reallocates Resources
The RAMP 203 trial in advanced KRAS G12C–mutated non-small cell lung cancer has been discontinued due to increased competition.
01-03 01:56
Verastem Oncology Announces Intent To Discontinue RAMP 203 Clinical Study In Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that following evaluation of interim data from the RAMP
2025-12-30 05:02
Verastem streamlines leadership team amid strategic transition
Verastem ( ($VSTM) ) has provided an update. On December 19, 2025, Verastem’s c...
2025-12-20 06:51
Verastem Oncology announces management changes
Verastem Oncology (NASDAQ:VSTM) announced on Monday strategic leadership changes to accelerate its next phase of growth. John Johnson has been appointed as chairman of the board of directors, succeedi...
2025-12-16 05:34
